Altimmune (ALT) Stock Forecast & Price Target

Altimmune is currently well-funded with $535 million in cash, which is expected to support the company's operations through the PERFORMA 52-week data readout in 2029. The company is making steady progress towards its Phase 3 pivotal study for pemvidutide, with FDA submission and final trial design alignment with EMA completed, and the trial is expected to commence in 2H26. Furthermore, Altimmune's pipeline beyond MASH, particularly the RECLAIM trial in AUD, provides additional potential catalysts for the company.

Altimmune is facing significant challenges in its pipeline development with a lack of near-term catalysts and a long timeline for its key candidate, pemvidutide, to complete its phase 2 RESTORE trial for ALD. The company also has a high risk of failure with only one key candidate and limited cash reserves, as well as potential competition from other companies targeting similar indications. Altimmune's financial stability is at risk due to a lack of near-term catalysts, limited cash reserves, and a high risk of failure with only one key candidate in its pipeline. Despite the recent advancement in RESTORE enrollment timing, the long timeline for pemvidutide's completion of its phase 2 trial for ALD increases the uncertainty surrounding the company's future success. Potential competition targeting similar indications also poses a threat to Altimmune's potential market share.